Infliximab in the treatment of psoriasis

References

• Elder JT. PSORS1: linking genetics and immunology. J. Invest. Dermatol.126, 1205–1206 (2006).
   PubMed Web of Science ®Google Scholar
• Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann. Rheum. Dis.64(Suppl. 2), ii14–ii17 (2005).
   PubMed Web of Science ®Google Scholar
• Mukhtar R, Choi J, Koo JY. Quality-of-life issues in psoriasis. Dermatol. Clin.22, 389–395 (2004).
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J. Am. Acad. Dermatol.41, 401–407 (1999).
   PubMed Web of Science ®Google Scholar
• Reynoso-von Drateln C, Martinez-Abundis E, Balcazar-Munoz BR, Bustos-Saldana R, Gonzalez-Ortiz M. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. J. Am. Acad. Dermatol.48, 882–885 (2003).
   PubMed Web of Science ®Google Scholar
• Mallbris L, Akre O, Granath F et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur. J. Epidemiol.19, 225–230 (2004).
   PubMed Web of Science ®Google Scholar
• Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA, Nurmohamed MT. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin. Arthritis Rheum.34, 585–592 (2004).
   PubMed Web of Science ®Google Scholar
• Crown WH, Bresnahan BW, Orsini LS, Kennedy S, Leonardi C. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr. Med. Res. Opin.20, 1929–1936 (2004).
   PubMed Web of Science ®Google Scholar
• Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS. Highly increased levels of tumor necrosis factor-α and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J. Rheumatol.24, 518–523 (1997).
   PubMed Web of Science ®Google Scholar
• Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-α (TNF-α) biological activity in psoriatic skin lesions. Clin. Exp. Immunol.96, 146–151 (1994).
   PubMed Web of Science ®Google Scholar
• Boyman O, Hefti HP, Conrad C, Nickoloff BJ, Suter M, Nestle FO. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-α. J. Exp. Med.199, 731–736 (2004).
   PubMed Web of Science ®Google Scholar
• Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α. Nature329, 630–632 (1987).
   PubMed Web of Science ®Google Scholar
• Matsuno H, Yudoh K, Katayama R et al. The role of TNF-α in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a study using a human RA/SCID mouse chimera. Rheumatology (Oxford)41, 329–337 (2002).
   PubMed Web of Science ®Google Scholar
• MacDermott RP. Alterations of the mucosal immune system in inflammatory bowel disease. J. Gastroenterol.31, 907–916 (1996).
   PubMed Web of Science ®Google Scholar
• Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine7, 251–259 (1995).
   PubMed Web of Science ®Google Scholar
• Van den Brande JM, Braat H, van den Brink GR et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology124, 1774–1785 (2003).
   PubMed Web of Science ®Google Scholar
• Di Sabatino A, Ciccocioppo R, Cinque B et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn’s disease. Gut53, 70–77 (2004).
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet366, 1367–1374 (2005).
   PubMed Web of Science ®Google Scholar
• Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet357, 1842–1847 (2001).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J. Am. Acad. Dermatol.51, 534–542 (2004).
   PubMed Web of Science ®Google Scholar
• Feldman SR, Gordon KB, Bala M et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br. J. Dermatol.152, 954–960 (2005).
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis. Br. J. Dermatol.154, 1161–1168 (2006).
   PubMed Web of Science ®Google Scholar
• Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N. Engl. J. Med.348, 601–608 (2003).
   PubMed Web of Science ®Google Scholar
• Centocor, Inc. Data on file. Module 2.7.4 summary of clinical safety psoriasis BLA.207, 209, 219 (2006).
   Google Scholar
• Listing J, Strangfeld A, Kary S et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum.52, 3403–3412 (2005).
   PubMed Web of Science ®Google Scholar
• Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factor-α antagonists. Pharmacotherapy25, 1181–1192 (2005).
   PubMed Web of Science ®Google Scholar
• Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor-α therapy. Arthritis Rheum.48, 3013–3022 (2003).
   PubMed Web of Science ®Google Scholar
• Askling J, Fored CM, Baecklund E et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann. Rheum. Dis.64, 1414–1420 (2005).
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch. Dermatol.139, 1425–1429 (2003).
   PubMed Web of Science ®Google Scholar
• Keystone EC. Advances in targeted therapy: safety of biological agents. Ann. Rheum. Dis.62(Suppl. 2), ii34–ii36 (2003).
   PubMedGoogle Scholar
• Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and cyclosporine: nested cohort crossover study. Lancet358, 1042–1045 (2001).
   PubMed Web of Science ®Google Scholar
• Paul CF, Ho VC, McGeown C et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J. Invest. Dermatol.120, 211–216 (2003).
   PubMed Web of Science ®Google Scholar
• Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn’s disease and rheumatoid arthritis. Am. J. Gastroenterol.99, 2385–2392 (2004).
   PubMed Web of Science ®Google Scholar
• Roberts L, McColl GJ. Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis. Intern. Med. J.34, 687–693 (2004).
   PubMed Web of Science ®Google Scholar
• Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-α antagonists. Drug Saf.27, 307–324 (2004).
   PubMed Web of Science ®Google Scholar
• Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A. Guidelines for using the QuantiFERON-TB gold test for detecting mycobacterium tuberculosis infection, United States. MMWR Recomm. Rep.54, 49–55 (2005).
   PubMedGoogle Scholar
• CDC. Tuberculosis associated with blocking agents against tumor necrosis factor-α, California, 2002–2003. MMWR Morb. Mortal. Wkly. Rep.53, 683–686 (2004).
   PubMedGoogle Scholar
• Reich K, Nestle FO, Papp K et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. Br. J. Dermatol.154, 1161–1168 (2006).
   PubMed Web of Science ®Google Scholar
• Antoni CE, Kavanaugh A, Kirkham B et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum.52, 1227–1236 (2005).
   PubMed Web of Science ®Google Scholar
• Sterry W, Barker J, Boehncke WH et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br. J. Dermatol.151(Suppl. 69), 3–17 (2004).
   PubMed Web of Science ®Google Scholar
• Sohn S, Schoeffski O, Prinz J et al. Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology212, 137–144 (2006).
   PubMed Web of Science ®Google Scholar
• Miller DW, Feldman SR. Cost-effectiveness of moderate-to-severe psoriasis treatment. Expert. Opin. Pharmacother.7, 157–167 (2006).
   PubMed Web of Science ®Google Scholar
• Newland MR, Weinstein A, Kerdel F. Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int. J. Dermatol.41, 449–452 (2002).
   PubMed Web of Science ®Google Scholar
• Schmick K, Grabbe J. Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor-α antibody (infliximab). Br. J. Dermatol.150, 367 (2004).
   PubMed Web of Science ®Google Scholar
• Heydendael VM, Spuls PI, Opmeer BC et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N. Engl. J. Med.349, 658–665 (2003).
   PubMed Web of Science ®Google Scholar
• Jacobsson LT, Turesson C, Gulfe A et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J. Rheumatol.32, 1213–1218 (2005).
   PubMed Web of Science ®Google Scholar
• Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol.152, 1304–1312 (2005).
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Matheson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch. Dermatol.139, 1627–1632 (2003).
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med.349, 2014–2022 (2003).
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum.52, 3279–3289 (2005).
   PubMed Web of Science ®Google Scholar
• Antoni C, Krueger GG, de Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis.64, 1150–1157 (2005).
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Antoni CE, Gladman DD et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann. Rheum. Dis. DOI:10.1136/ard.2005.045658 (2006).
   Google Scholar
• Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum.50, 2264–2272 (2004).
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J. Rheumatol.33, 712–721 (2006).
   PubMed Web of Science ®Google Scholar
• Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J. Pharmacol. Exp. Ther.301, 418–426 (2002).
   PubMed Web of Science ®Google Scholar